

## **Product datasheet for TL309651V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **SAR1B Human shRNA Lentiviral Particle (Locus ID 51128)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** SAR1B Human shRNA Lentiviral Particle (Locus ID 51128)

**Locus ID:** 51128

Synonyms: ANDD; CMRD; GTBPB; SARA2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: SAR1B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001033503, NM 016103, NM 016103.1, NM 016103.2, NM 016103.3, NM 001033503.1,

NM 001033503.2, BC093034, BC093034.1, BC002847, BM765118, NM 016103.4,

NM 001033503.3

UniProt ID: Q9Y6B6

**Summary:** The protein encoded by this gene is a small GTPase that acts as a homodimer. The encoded

protein is activated by the guanine nucleotide exchange factor PREB and is involved in protein transport from the endoplasmic reticulum to the Golgi. This protein is part of the COPII coat complex. Defects in this gene are a cause of chylomicron retention disease (CMRD), also known as Anderson disease (ANDD). Two transcript variants encoding the same

protein have been found for this gene. [provided by RefSeq, Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).